AI Article Synopsis
- Atherosclerotic cerebral infarction (ACI) has high rates of mortality and disability, with recent studies highlighting the role of the OX40/OX40L co-stimulatory signal in aggravating atherosclerosis in patients.
- Researchers investigated how rosuvastatin affects the expression of OX40L and PPAR-γ in human endothelial cells and lymphocytes, finding that OX-LDL stimulates OX40L while inhibiting PPAR-γ expression.
- The study concluded that rosuvastatin can counteract these effects, reducing OX40L levels in patients and suggesting its potential as a treatment for managing atherosclerosis in ACI.
Article Abstract
Atherosclerotic cerebral infarction (ACI) is characterized by extremely high fatality and disability rate. Recent studies indicate that co-stimulatory signal of tumor necrosis factor superfamily OX40/OX40L contributes to the atherosclerosis effect in ACI patients. However, it remains unclear the mechanism underlying the anti-atherosclerosis process. So this study aims to investigate the effects of rosuvastatin on the expression of OX40L, peroxisome proliferator-activated receptors gamma (PPAR-γ) in human umbilical vein endothelial cells (HUVEC), and human peripheral blood lymphocytes. Different concentration of rosuvastatin and oxidized low-density lipoprotein (OX-LDL) co-intervene HUVEC to observe the expression of OX40L and PPAR-γ using real-time quantitative RT-PCR (Q-RTPCR) and Western-blot. Furthermore, we examined the level changes of plasmic sOX40L and hs-CRP in acute atherosclerotic cerebral infarction patients. The results demonstrated that concentration-dependent and time-dependent OX-LDL remarkably stimulate the expression of OX40L and inhibit the expression of PPAR-γ in vitro. But concentration-dependent rosuvastatin can reverse the impact of OX-LDL, suggesting that rosuvastatin can prevent the expression of OX40L, and the process may be associated with mevalonate pathway. In vivo, acute atherosclerotic cerebral infarction patients taking 20 mg rosuvastatin exhibited significantly reduced expression of OX40L in peripheral blood lymphocyte, sOX40L in blood plasma, and hs-CRP compared with before treatment. Our studies identified rosuvastatin as an effective medicine in controlling atherosclerosis process in ACI by inhibiting OX40L and stimulating PPAR-γ expression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12031-013-0134-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functionalized aluminum hydroxide-based self-adjuvanted nanovaccine orchestrates antitumor immune responses via Dectin-1 signaling.
J Control Release
December 2024
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Centre for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, People's Republic of China. Electronic address:
Self-adjuvanted vaccine delivery platforms possess potential for targeted delivery of antigens and initiation of potent immune responses. Although aluminum-containing adjuvants have been approved and widely used in human vaccines, their effectiveness in inducing Th1-type immune responses is far from satisfactory. To facilitate antigen delivery and activate potent antitumor immune responses, a self-adjuvanted nanovaccine (CPBG-Al@OVA) is constructed by functionalizing aluminum hydroxide with β-1,3-glucan, which recognizes pattern recognition receptors via Dectin-1.
View Article and Find Full Text PDFEffects of Huang-Lian-Jie-Du decoction on improving skin barrier function and modulating T helper cell differentiation in 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis mice.
Front Pharmacol
November 2024
School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Atopic dermatitis (AD) is among the most frequently encountered skin diseases, bothering a considerable number of patients. Today, corticosteroids and antihistamines are among the numerous drugs applied for the therapy of AD. However, lengthy use of them contributes to side effects, such as physiological changes in skin.
View Article and Find Full Text PDFComparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis.
Allergy
November 2024
Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA.
Article Synopsis
- Blocking IL-13 is effective for treating atopic dermatitis (AD), and new research suggests that targeting T cell costimulatory molecules like OX40 and OX40L could also be a beneficial treatment option.
- This study investigates whether targeting CD30L might be an additional therapeutic avenue, by comparing it with existing targets like IL-13 and OX40L using single-cell RNA-seq and a murine model of AD.
- Results showed that blocking CD30L effectively reduced disease symptoms in mice, indicating that targeting the CD30-CD30L pathway could be a promising future treatment for human atopic dermatitis, similar to targeting the OX40-OX40L pathway.
Making the effect visible - OX40 targeting nanobodies for imaging of activated T cells.
Front Immunol
October 2024
Pharmaceutical Biotechnology, University Tübingen, Tübingen, Germany.
Purpose: Human OX40 (hOX40/CD134), a member of the TNF receptor superfamily, is mainly expressed on activated T lymphocytes. Triggered by its ligand OX40L (CD252), it provides costimulatory signals that support the differentiation, proliferation and long-term survival of T cells. Besides being a relevant therapeutic target, hOX40 is also an important biomarker for monitoring the presence or infiltration of activated T cells within the tumor microenvironment (TME), the inflammatory microenvironment (IME) in immune-mediated diseases (IMIDs) and the lymphatic organs.
View Article and Find Full Text PDFImmune marker expression and prognosis of early breast cancer expressing HER3.
Eur J Cancer
December 2024
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; Translational Medicine, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. Electronic address:
Introduction: There is a strong rationale for targeting HER3, as HER3 contributes to tumorigenesis and treatment resistance. However, the prognostic role of HER3 and their association with immunoregulatory protein expression has not been established.
Methods: The main objective of this study was to investigate the prognostic role of HER3 expression and identify immunoregulatory marker expression according to HER3 status.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!